LEXICON PHARMACEUTICALS INC (LXRX) Stock Fundamental Analysis
USA - NASDAQ:LXRX - US5288723027 - Common Stock
1.375 USD
-0.06 (-4.51%)
We assign a fundamental rating of 3 out of 10 to LXRX. LXRX was compared to 531 industry peers in the Biotechnology industry. LXRX may be in some trouble as it scores bad on both profitability and health. LXRX is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year LXRX has reported negative net income.
In the past year LXRX has reported a negative cash flow from operations.
LXRX had negative earnings in each of the past 5 years.
LXRX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
LXRX has a Return On Assets (-53.47%) which is comparable to the rest of the industry.
LXRX has a Return On Equity (-93.19%) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -53.47% | ||
| ROE | -93.19% | ||
| ROIC | N/A |
ROA(3y)-65.6%
ROA(5y)-57.94%
ROE(3y)-138.18%
ROE(5y)-105.86%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of LXRX (99.18%) is better than 97.74% of its industry peers.
LXRX's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for LXRX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 99.18% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.67%
GM growth 5Y-0.19%
2. Health
2.1 Basic Checks
LXRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for LXRX has been increased compared to 1 year ago.
The number of shares outstanding for LXRX has been increased compared to 5 years ago.
Compared to 1 year ago, LXRX has an improved debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -9.97, we must say that LXRX is in the distress zone and has some risk of bankruptcy.
LXRX's Altman-Z score of -9.97 is on the low side compared to the rest of the industry. LXRX is outperformed by 72.50% of its industry peers.
LXRX has a Debt/Equity ratio of 0.43. This is a healthy value indicating a solid balance between debt and equity.
LXRX's Debt to Equity ratio of 0.43 is on the low side compared to the rest of the industry. LXRX is outperformed by 71.94% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.43 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -9.97 |
ROIC/WACCN/A
WACC9.28%
2.3 Liquidity
LXRX has a Current Ratio of 4.16. This indicates that LXRX is financially healthy and has no problem in meeting its short term obligations.
LXRX's Current ratio of 4.16 is in line compared to the rest of the industry. LXRX outperforms 48.78% of its industry peers.
LXRX has a Quick Ratio of 4.16. This indicates that LXRX is financially healthy and has no problem in meeting its short term obligations.
LXRX has a Quick ratio of 4.16. This is comparable to the rest of the industry: LXRX outperforms 49.91% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.16 | ||
| Quick Ratio | 4.16 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 74.67% over the past year.
Looking at the last year, LXRX shows a very strong growth in Revenue. The Revenue has grown by 2481.48%.
Measured over the past years, LXRX shows a very negative growth in Revenue. The Revenue has been decreasing by -37.35% on average per year.
EPS 1Y (TTM)74.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%77.78%
Revenue 1Y (TTM)2481.48%
Revenue growth 3Y369.67%
Revenue growth 5Y-37.35%
Sales Q2Q%710.4%
3.2 Future
LXRX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.37% yearly.
LXRX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 73.16% yearly.
EPS Next Y69.21%
EPS Next 2Y25.01%
EPS Next 3Y18.64%
EPS Next 5Y13.37%
Revenue Next Year355.96%
Revenue Next 2Y4.9%
Revenue Next 3Y35.41%
Revenue Next 5Y73.16%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for LXRX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LXRX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as LXRX's earnings are expected to grow with 18.64% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.01%
EPS Next 3Y18.64%
5. Dividend
5.1 Amount
LXRX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:LXRX (11/14/2025, 9:39:11 AM)
1.375
-0.06 (-4.51%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners72.01%
Inst Owner Change-0.49%
Ins Owners0.86%
Ins Owner Change0.15%
Market Cap499.68M
Revenue(TTM)31.08M
Net Income(TTM)-120.62M
Analysts80
Price Target2.81 (104.36%)
Short Float %7.48%
Short Ratio11.6
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)71.13%
Min EPS beat(2)29.61%
Max EPS beat(2)112.65%
EPS beat(4)3
Avg EPS beat(4)41.42%
Min EPS beat(4)-7.28%
Max EPS beat(4)112.65%
EPS beat(8)7
Avg EPS beat(8)23.99%
EPS beat(12)9
Avg EPS beat(12)13.92%
EPS beat(16)13
Avg EPS beat(16)12.01%
Revenue beat(2)1
Avg Revenue beat(2)234.48%
Min Revenue beat(2)-12.42%
Max Revenue beat(2)481.39%
Revenue beat(4)2
Avg Revenue beat(4)182.32%
Min Revenue beat(4)-41.43%
Max Revenue beat(4)481.39%
Revenue beat(8)2
Avg Revenue beat(8)66.06%
Revenue beat(12)3
Avg Revenue beat(12)55.44%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)6.59%
EPS NQ rev (1m)0%
EPS NQ rev (3m)20%
EPS NY rev (1m)0%
EPS NY rev (3m)50.39%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-5.5%
Revenue NY rev (1m)0%
Revenue NY rev (3m)266.92%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 8.55 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 3.86 | ||
| P/tB | 5.89 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.19
EYN/A
EPS(NY)-0.28
Fwd EYN/A
FCF(TTM)-0.28
FCFYN/A
OCF(TTM)-0.28
OCFYN/A
SpS0.16
BVpS0.36
TBVpS0.23
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -53.47% | ||
| ROE | -93.19% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 99.18% | ||
| FCFM | N/A |
ROA(3y)-65.6%
ROA(5y)-57.94%
ROE(3y)-138.18%
ROE(5y)-105.86%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.67%
GM growth 5Y-0.19%
F-Score6
Asset Turnover0.26
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.43 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 129.52% | ||
| Cap/Sales | 1.34% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.16 | ||
| Quick Ratio | 4.16 | ||
| Altman-Z | -9.97 |
F-Score6
WACC9.28%
ROIC/WACCN/A
Cap/Depr(3y)200.97%
Cap/Depr(5y)201.27%
Cap/Sales(3y)447.45%
Cap/Sales(5y)348.55%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)74.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%77.78%
EPS Next Y69.21%
EPS Next 2Y25.01%
EPS Next 3Y18.64%
EPS Next 5Y13.37%
Revenue 1Y (TTM)2481.48%
Revenue growth 3Y369.67%
Revenue growth 5Y-37.35%
Sales Q2Q%710.4%
Revenue Next Year355.96%
Revenue Next 2Y4.9%
Revenue Next 3Y35.41%
Revenue Next 5Y73.16%
EBIT growth 1Y39.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year63.12%
EBIT Next 3Y13.3%
EBIT Next 5YN/A
FCF growth 1Y8.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y8.04%
OCF growth 3YN/A
OCF growth 5YN/A
LEXICON PHARMACEUTICALS INC / LXRX FAQ
What is the fundamental rating for LXRX stock?
ChartMill assigns a fundamental rating of 3 / 10 to LXRX.
Can you provide the valuation status for LEXICON PHARMACEUTICALS INC?
ChartMill assigns a valuation rating of 0 / 10 to LEXICON PHARMACEUTICALS INC (LXRX). This can be considered as Overvalued.
Can you provide the profitability details for LEXICON PHARMACEUTICALS INC?
LEXICON PHARMACEUTICALS INC (LXRX) has a profitability rating of 2 / 10.
What is the earnings growth outlook for LEXICON PHARMACEUTICALS INC?
The Earnings per Share (EPS) of LEXICON PHARMACEUTICALS INC (LXRX) is expected to grow by 69.21% in the next year.